// App-Quantinova.ai

577 : Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).

Researchers

Presenter

  • Heather M. Moore

Principal Investigators

  • Meritxell Bellet

  • Begoa Bermejo De Las Heras

  • Maria Gin Corts

  • Catherine Oakman

  • Peter Schmid

  • Xuan Bich Trinh

  • Duncan Wheatley

  • Komal L. Jhaveri

  • Peter Kabos

  • Elgene Lim

  • Thierry Velu

  • Ciara Metcalfe

  • Mary R. Gates

  • Ching-Wei Chang

  • John Bond

  • Leonard D Goldstein

  • Jennifer O'Hara Lauchle

  • Aditya Bardia

Medical Centers

  • Genentech, Inc., South San Francisico, CA

  • START Madrid, Centro Integral Oncologico Clara Campal, Hospital Universitario Norte Sanchinarro, Madrid, Spain

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Clinic University Hospital, Biomedical Research Institute, INCLIVA Hospital, Valencia, Spain

  • Hospital Universitario Ramón y Cajal, IOB Institute of Oncology, Quiron Group, Madrid, Spain

  • Sunshine Hospital, St Albans, Australia

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Antwerp University Hospital, Edegem, Belgium

  • Royal Cornwall Hospital, Truro, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Colorado Cancer Center, Aurora, CO

  • Connie Johnson Breast Cancer Research Laboratory, Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, Australia

  • Chirec Cancer Institute, Brussels, Belgium

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • United States

  • Spain

  • Australia

  • United Kingdom

  • Belgium

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Progesterone receptor

  • Proliferation marker protein Ki-67

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • N/A

Study Id's

  • NCT03916744

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved